AsianScientist (Oct. 12, 2016) – China-based WuXi AppTec (WuXi), a pharmaceutical, biotechnology, and medical device technology platform company, has opened their new 150,000 sq ft biomanufacturing facility in the Philadelphia Navy Yard.
The new facility will supplement WuXi’s existing 20,000-sq ft current good manufacturing practice (cGMP) cell therapy manufacturing facility, as well as a 50,000 sq ft facility for the commercial manufacturing of allogeneic and autologous cell-based therapeutics. WuXi’s total manufacturing capacity in the US now stands at 220,000 sq ft.
This facility is designed for cell therapy products that use viral vectors such as chimeric antigen receptor T-cell therapies. In addition, the facility will permit expansion of viral vector manufacturing to support gene therapy clinical and commercial programs and will permit large-scale production in 2,000 L single-use bioreactors. When fully configured, the facility could employ an additional 200 manufacturing and support staff.
———
Source: WuXi AppTec.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
